Evaluation of DNA topoisomerase IIα expression provides independent prognostic information in non‐Hodgkin's lymphomas

Korkolopoulou, Penelope; Angelopoulou, Maria K.; Siakantari, M; Mitropoulos, Fotios; Vassilakopoulos, T.; Zorzos, Haralambos; Rassidakis, George Z.; Androulaki, Athina; Patsouris, E; Kittas, Christos; Davaris, P; Pangalis, Gerassimos A.

doi:10.1046/j.1365-2559.2001.01036.x

Cited by 15 publications

(26 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prognostic value of topo IIa expression in other malignancies (breast carcinomas, non-Hodgkin's lymphomas, Hodgkin's disease) has been investigated before. [23][24][25][26] High topo Figure 3 Overall survival time of 95 patients with MCL and different IPI scores (log-rank test, univariate analysis).…”

Section: Resultsmentioning

confidence: 99%

“…36 Ki-S4 is not commercially available, but an equivalent antibody was used by others (Novocastra, Clone 3FG). 26 Primary antibodies were then incubated on the sections for 60 min at room temperature. The immunoreactions were enhanced by means of the alkaline phosphatase-antialkaline phosphatase (APAAP) method 37 followed by brief counterstaining with Mayer's hematoxylin.…”

Section: Immunohistochemistrymentioning

confidence: 99%

“…In each case, nuclei from 500 neoplastic cells from randomly selected fields of the whole section were counted and the Ki-S4 (topo IIa) and Ki-S5 (Ki-67) index was calculated as the percentage of positive nuclei. 26,27 All nuclear staining was counted as topo IIa ( Figures 1 and 2) or Ki-67 positivity. A hematological cell counter (Statitest L10, Ferrari, Berlin, Germany) was used for counting.…”

Section: Immunohistochemistrymentioning

confidence: 99%

“…26,27 The aim of this study was to gain more precise information about the topo IIa activity in MCL. We chose cases from two former large studies (1975)(1976)(1977)(1978)(1979)(1980)(1981)(1982)(1983)(1984)(1985) with long follow-up data (up to 15 years) and in the majority of cases (around 90%) without a treatment containing topo inhibitors.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Topoisomerase IIα expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome

et al. 2004

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) is a malignant lymphoma associated with a relatively aggressive clinical course and a median overall survival time of 3-4 years. Treatment usually consists of combination chemotherapy, often including topoisomerase (topo) inhibitors such as doxorubicin, etoposide and mitoxantrone. Topo IIa is an enzyme that is needed whenever uncoiling of DNA is necessary during the cell cycle. The enzyme is a marker of cell proliferation. We analyzed the expression of topo IIa in relation to Ki-67 and the clinical outcome in patients with MCL. Biopsy specimens from 95 untreated patients enrolled in two multicenter trials (1975)(1976)(1977)(1978)(1979)(1980)(1981)(1982)(1983)(1984)(1985) were investigated immunohistochemically with monoclonal antibodies against topo IIa (Ki-S4) and Ki-67 (Ki-S5). Patients with low (0-10%) topo IIa expression had a median overall survival time of 49.0 months, compared to 17.0 months for patients with high (more than 10%) topo IIa expression. The Kaplan-Meier analysis showed a significant difference in the overall survival time related to the percentage of topo IIa (Po0.001) and Ki-67 (Po0.001) positive tumor cells. Multivariate Cox regression analysis revealed the expression of topo IIa as the most important prognostic factor (Po0.001) in MCL superior to the international prognostic index (IPI), the Ki-67 index and other clinical characteristics.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Immunohistochemistrymentioning

confidence: 99%

Section: Immunohistochemistrymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Topoisomerase IIα expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Meanwhile, topoisomerase II a is highly expressed on aggressive B-cell non-Hodgkin's lymphomas; on the other hand, its expression on T-cell malignancies appears to be generally low, although this conclusion is based on studies with limited samples (Holden et al, 1995;Turley et al, 1997;Korkolopoulou et al, 2001). Our current data with the human T-cell leukaemia cell line Jurkat suggest that the expression of CD26 may be potentially linked to high topoisomerase II a level in selected T-cell malignancies, which are generally aggressive and often difficult to treat at the present time.…”

Section: Discussionmentioning

confidence: 99%

Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors

et al. 2003

View full text Add to dashboard Cite

CD26/dipeptidyl peptidase IV (DPPIV) is a surface antigen with multiple functions, including a role in T-cell activation and the development of certain human cancers. We previously demonstrated that CD26/DPPIV enhanced sensitivity of Jurkat cells to doxorubicin. We now show that expression of CD26/DPPIV enhanced sensitivity of CD26 Jurkat transfectants to G 2 -M arrest mediated by the antineoplastic agent etoposide. The increased sensitivity to etoposide-induced G 2 -M arrest was associated with disruption of cell cycle-related events, including hyperphosphorylation of p34 cdc2 kinase, change in cdc25C expression and phosphorylation, and alteration in cyclin B1 expression. CD26/DPPIV-associated enhancement of doxorubicin and etoposideinduced G 2 -M arrest was also observed in serum-free media, suggesting an effect of CD26 on cell-derived processes rather than serum-derived factors. Importantly, our work elucidated a potential mechanism for the enhanced susceptibility of CD26-expressing Jurkat cells to the topoisomerase II inhibitors by demonstrating that CD26/DPPIV surface expression was associated with increased topoisomerase II a levels and enhanced enzyme activity. Besides being the first to show a functional association between the multifaceted molecule CD26 and the key cellular protein topoisomerase II a, our studies provide additional evidence of a potential role for CD26 in the treatment of selected malignancies.

show abstract

Positron Emission Tomography Imaging of Cell Proliferation in Oncology

2004

View full text Add to dashboard Cite

Evaluation of DNA topoisomerase IIα expression provides independent prognostic information in non‐Hodgkin's lymphomas

Cited by 15 publications

References 30 publications

Topoisomerase IIα expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome

Topoisomerase IIα expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome

Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors

Positron Emission Tomography Imaging of Cell Proliferation in Oncology

Contact Info

Product

Resources

About